{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(5)"],"submitter":["Tibullo D"],"pubmed_abstract":["The proteasome inhibitor bortezomib (BTZ) has emerged as an effective drug for the treatment of multiple myeloma even though many patients relapse from BTZ therapy. The present study investigated the metabolic pathways underlying the acquisition of bortezomib resistance in multiple myeloma. We used two different clones of multiple myeloma cell lines exhibiting different sensitivities to BTZ (U266 and U266-R) and compared them in terms of metabolic profile, mitochondrial fitness and redox balance homeostasis capacity. Our results showed that the BTZ-resistant clone (U266-R) presented increased glycosylated UDP-derivatives when compared to BTZ-sensitive cells (U266), thus also suggesting higher activities of the hexosamine biosynthetic pathway (HBP), regulating not only protein O- and N-glyc"],"journal":["Biomolecules"],"pagination":["E696"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7277183"],"repository":["biostudies-literature"],"pubmed_title":["Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells."],"pmcid":["PMC7277183"],"pubmed_authors":["Raimondo FD","Wissam Saab M","Parenti R","Giallongo C","Vicario N","Amorini AM","Volti GL","Barbato A","Palumbo GA","Romano A","Puglisi F","Lazzarino G","Tavazzi B","Tibullo D","Mangione R","Brundo MV"],"additional_accession":[]},"is_claimable":false,"name":"Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells.","description":"The proteasome inhibitor bortezomib (BTZ) has emerged as an effective drug for the treatment of multiple myeloma even though many patients relapse from BTZ therapy. The present study investigated the metabolic pathways underlying the acquisition of bortezomib resistance in multiple myeloma. We used two different clones of multiple myeloma cell lines exhibiting different sensitivities to BTZ (U266 and U266-R) and compared them in terms of metabolic profile, mitochondrial fitness and redox balance homeostasis capacity. Our results showed that the BTZ-resistant clone (U266-R) presented increased glycosylated UDP-derivatives when compared to BTZ-sensitive cells (U266), thus also suggesting higher activities of the hexosamine biosynthetic pathway (HBP), regulating not only protein O- and N-glyc","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2025-05-29T19:19:00.653Z","creation":"2025-05-29T19:19:00.653Z"},"accession":"S-EPMC7277183","cross_references":{"pubmed":["32365811"],"doi":["10.3390/biom10050696"]}}